Here are five things to know:
1. Enterome will receive a$50 million upfront payment and commitment from Takeda to make a future equity investment in the biotech company. Enterome may also receive up to $640 million for achieving specific clinical development, regulatory and commercial milestones with EB8018.
2. Under the agreement, Takeda and Enterome will co-develop EB8018. If approved, the product will be co-promoted in the U.S. under a profit/cost-sharing structure.
3. EB8018 is an orally-administered, gut-restricted, small molecule designed to selectively disable gut bacteria that can cause inflammation without disrupting the local microbiome.
4. A phase 1A trial demonstrated EB8018 administration in the examined dose range was safe and exhibited minimal blood absorption. A phase 1B study testing the safety and efficacy of EB8018 in patients with active Crohn’s disease is currently underway.
5. This is the second collaboration between Enterome and Takeda. In 2016, the companies entered a strategic drug discovery collaboration focused on microbiome targets across several gastrointestinal diseases, including inflammatory bowel disease and motility disorders.
More articles on gastroenterology:
Dr. Richard Blumberg earns spot in National Academy of Medicine — 3 insights
Central Maine Healthcare adds medical director in Dr. Sean McGarr — 4 insights
Austin Gastroenterology signs on to anchor large development — 3 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
